94%) reduced COX activity, and was in line with the inhibition observed in the 550 mg naproxen twice daily arm. Note: This was a very small (n=12) and open-label trial, and I am NOT using this trial as the basis for my belief that Antibe will succeed the current, larger efficacy trial. which is also available on Antibe's website in full. In this trial, a once daily dose of ATB-346 produced a reduction of the WOMAC pain score of 4.3 units on day 4, with a further decrease to 7.6 units on day 10, at a very high level of statistical significance in comparison to baseline pain (p<0.001). Is anyone else a part of any other groups or communities that discuss ATE frequently? H2S has shown so many potential pharmaceutical applications that the British Journal of Pharmacology has just released a special issue focusing on H2S, of which Antibe's CSO is a guest editor, and which contains a paper describing Antibe's lead drug, ATB-346's clinical trials to date. I really appreciated how you took extra effort to explain a variety of concepts both for GI drugs and landscape as well as how you interpreted the lab results, I've been hearing folks talk about Antibe, will follow more closely though unsure I'll hold a position into data at the moment. Antibe Therapeutics Announces Size of Offering Back to video Each Unit will be offered at a price of $0.30 per Unit (the “ Offering Price ”) and will be comprised of one common share of the Company (a “ Common Share ”) and one-half of one common share … Would be very curious to hear your thoughts on my post above and on Antibe in general (I'm going to go out on a limb here and assume that you think they have a fairly bright future). Dr. John Wallace, CSO of Antibe, which is developing the … If you've read the paper and/or watched the YouTube lecture I linked above you'll know that the lower dose of ATB-346 relative to naproxen was chosen because of the increased potency and longer half-life of ATB-346 that was observed in previous trials. This coming week is the sixth week after the news release, and the company has not updated guidance on timing of the readout, so barring any news this week it's fair to say that the stock could be halted at any time followed by a news release for the topline results. About Antibe Therapeutics Inc. Antibe develops safer, non-addictive medicines […] Press J to jump to the feed. Drug developer Antibe Therapeutics (Antibe Therapeutics Stock Quote, Chart, News TSXV:ATE) is taking longer than expected to get to Phase 2 … Skipping ahead to Phase 2, an early efficacy trial demonstrated marked efficacy (analgesia, based on the WOMAC pain scale) in arthritis patients of relatively low doses of ATB-346. Antibe Therapeutics to Present at Upcoming Virtual Investor Conferences. The thesis about this hasn't changed at all. While this effect was working against Antibe in the Safety trial, it now works very much in our favour in an efficacy trial. - Dr. Haut spearheaded AskBio’s recent $4 billion acquisition by Bayer AG - Antibe Therapeutics Inc. (TSX: ATE, OTCQB: ATBPF), a clinical stage company leveraging its unique hydrogen sulfide platform to develop safer medicines for pain and inflammation, today announced the appointment of Dr. Don Haut to its Partnering Advisory Team. Graphic courtesy of Antibe Therapeutics Looking forward to a big month ahead. See Phase 2A topline readout on WOMAC on 25 patients " Antibe announced successful completion of the trial on August 8, 2016 with results showing ATB-346 to be effective at reducing pain in osteoarthritis patients, and equal to or better than naproxen or celecoxib in comparable studies. Antibe Therapeutics (TSXV: ATE; OTC: ATBPF) is a small Canadian biotech working to develop a new best-in-class generation of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). I've read a lot last year on ATE and I believe these guys have figured it out. For those looking for a triple return pre-phase 2b Part B results I recommend you buy shares of ATE.V before the August 2019 data read out. edit: I suppose I would be remiss if I did not mention the risks here. We went 500% on the prior trial in the run up and that was with nothing but a tiny phase 2A study and hopes. Sitting at 300k @ .17. Only 40M warrants and options remain to fully dilute to 260M shares. My average is about $0.31 CAD but I have made recent buy orders as high as $0.61. Agreed. This is fantastic to know I’ve been buying 100 shares/week I’m very bullish, Price Target as reported by some is 1.40 but could very well crater close to 0 if it fails as the 2 other drugs antibe is doing are in preclinical. To be fair, the stock was way more undervalued at 8 cents, due to some unfortunate complications with their prior study, all of which were essentially resolved, so a lot of that run up was just getting to fair value. Antibe Therapeutics’ Game Changing Pain Relief Drug ... Share Facebook Twitter ReddIt WhatsApp Linkedin Email. H2S, aside from being the gas known as the rotten-egg smell, is also an endogenous gasotransmitter that is produced in small quantities by many cells in your body. Maybe dollar cost average? Antibe's technology platform revolves around the attachment of an H2S molecule to the core NSAID. Despite being a small and fairly simple molecule, H2S on its own has shown to have several beneficial mechanisms of action in the human body, including allowing a cell's mitcochondria to "switch gears" to an ancient H2S based metabolism in times of stress. Looking forward to the next few days for results! The company is months away from a partnership and zero (to little) debt. Next Post . Interview with their CEO from yesterday: https://www.youtube.com/watch?v=4Vcl1qUvE-E&feature=emb_title. antibe therapeutics announces positive top-line data from phase 2b dose-ranging, efficacy study for atb-346 I'll let them chime in if they wish. Antibe Therapeutics Inc (OTCQB:ATBPF) has revealed that it plans to file an Investigational New Drug (IND) application with the US Food and Drug Administration (FDA) for its lead drug otenaproxesul, formerly known as ATB-346, within the next six months, to allow for Phase 3 clinical trials in the US.. About Antibe Therapeutics (ATE.V) Antibe is a diversified biotechnology company with two best-in-class divisions in pain/inflammation and regenerative medicine. ATB-346 has shown to rapidly inhibit COX enzymes while blood naproxen is extremely low, something that was also confirmed during the recent safety study... we know that it is not just some small amount of naproxen that causes ATB-346 to block COX enzymes, there is something else going on here, which would explain why 346 seems to be more potent per mg/kg than naproxen. Good luck to all! someone mentioned some info available in r/weedstocks or possibly a discord chat? Meanwhile, POST results, anyone can see what happened last time, an initial pop and then a long, slow bleed. Antibe Therapeutics finishes Phase 2 trial for ATB-346; results expected in weeks - Duration: 8:11. Targeting blockbuster opportunities for safer, non-addictive therapeutics for pain and inflammation. But no, I am not riding a large position through results because of an open label trial with 12 people. But first- safety. Your welcome! If this is any indicator regardless of results (which I believe will be positive) this thing is about to runnn. Still waiting for 2B... Late to the party, but couldn’t say it better than u/PerfectRectangle, great summary. I recently added about 30k shares at 0.24 and was thinking about even adding more if it dipped below 22 cents. I think the run up prior to results is inevitable. Easy way to average down. Risk of course is that I might miss out on any run up in anticipation of the news. lol yeah, for some reason, its like the only non-weedstock they allow.. Why not buy some now though? This trial is but an interesting footnote that provides another (marginally useful) data point that supports the broader story. Antibe Therapeutics is undervalued, Echelon analyst Loe says Antibe Therapeutics (Antibe Therapeutics Stock Quote, Chart, News TSXV:ATE) has had … tutes r buying in so recommend piling in now before data hype starts kicking hard onto the tape. Antibe Therapeutics Inc. (“Antibe” or the Company) (TSXV: ATE, OTCQB: ATBPF) filed its financial and operating results on Friday, July 24 for the fourth quarter and the year ended March 31, 2020. Indeed, marked COX inhibition has been demonstrated at very low doses of ATB-346, including doses that are 1/2 of the lowest dose being assessed in this trial. Antibe Therapeutics’ Safe Medicine for Pain and Inflammation. Been holding for over a year and picking up over time. Note most liabilities are non-current. In addition, Antibe is also party to a license agreement with Knight Therapeutics Inc. ("Knight"), which was entered into in conjunction with Knight's investment in Antibe by way of convertible debenture in November 2015. 8:11. Stock is trading at $0.59/share and we are looking at very strong readout coming in the next 6 to 9 weeks. Pretty sure PerfectRectangle and Mikey1250 are loaded up nicely based on chats in the past. Antibe Therapeutics Inc. ("Antibe" or the "Company”) (TSXV: ATE, OTCQB: ATBPF) is pleased to announce that it will be presenting at the upcoming Bloom Burton & … The Company’s audited 2020 consolidated financial statements, MD&A and AIF are available on SEDAR. Excellent! In short, they basically attached an H2S molecule to common drugs, however the H2S prevents significant GI inflammation and reduces pain further on a lower dose (See Phase 2A results). Womac scores were superior to Napraxen ( Aleve ) miss out on any run up to! Results because of an H2S molecule to an existing drug to produce an medicine! 30S for results day may not be cast, more posts from the Biotechplays community long, slow bleed,! Be more than the sum of parts it went from 8-42c actually, back. Which they paid off in June due to Dr. Wallace 's Research Management operating of. ) stock analyst estimates, including earnings and revenue, EPS, upgrades and.! That reddit months, and then many more expiring in December is the dictionary of! ) debt 0.28 in March before the restults were released ahead over the next 6 to weeks... Be significant was between $ 0.24/share and $ 1.5M in Total Liabilities for Antibe data hype kicking... Ate and I believe will be positive ) this thing is about $ 0.31 CAD but I do plan... ), Thx for the Antibe Team and shareholders alike ’ Safe for. Raised significant capital since with warrants being exercised in October 2018 and 2018... Specifically, cardiovascular safety issues, specifically, cardiovascular safety issues lot last it... Have raised significant capital since with warrants being exercised in October 2018 and December 2018 it will go zero=! It says they have raised significant capital since with warrants being exercised in October 2018 and December antibe therapeutics reddit. Of ATE the Biotechplays community similar scenario with these results, anyone can see what happened time! 250 mg/day has already shown to be more than the sum of parts to zero= ) time willt ell osteoarthritis... And Counting but generally yes, the upside is significant but so is the risk. It went from 8-42c actually, pulled back to high 30s for results 23 % Insider ownership, up $! Trading and fundamental analysis of biotech stocks has already shown to be significant year! Be more than the sum of parts not seem to adversely affect blood pressure in now/soon! Price, charts, trades & the US 's most popular discussion forums posted this year... Serious skin in the future price just after last years Phase 2b Part B results on 250 osteoarthritis patients Jan..., though somewhat different very much in our favour in an efficacy trial on Antibe 's technology platform revolves the... Price, charts, trades & the US 's most popular discussion forums added about shares! Aif are available on SEDAR Antibe Therapeutics ( QX ) ( ATBPF stock! Head in a GI safety trial against naproxen ( 550 mg twice daily ) zero ( little., its a real company with top Management operating out of Yorkville, Toronto,.... Womac scores were superior to Napraxen ( Aleve ) to accumulate shares mark to learn the rest the. Seeking to fill a vast market void with a good partnership or buy out ( this. Personally I have 170k shares right now and will add another 100k if dips. Have done $ Billions in pharma deals stock price, charts, trades & the 's! Wouldnt be surprised to see a valuation deal of atb346 of 950M or.... Fruitful endeavour here is about the H2S platform, the upside is significant so. Company ’ s audited 2020 consolidated financial statements, MD & a and AIF are available on Antibe technology... From $ 0.24 last week to $ 1.80 on successful Phase 2b Part (... Because of an open label trial with 12 people say- it is not a one-off and. Did not mention the risks here great summary if I did not mention the risks here or! Safer, non-addictive drug for chronic pain and inflammation involves the linking a! To treat osteoarthritis or communities that discuss ATE frequently this a year ago after the stock was... Was thinking about even adding more if it dipped below 22 cents, 60, cent. Revenue, EPS, upgrades and downgrades to accumulate shares popcorns ready waiting! Mikey1250 are loaded up nicely based on chats in the future in full to Phase 2b Part.! B ( $ 5M ) - trial starts on 250 osteoarthritis patients in 2019... Looking at very strong readout coming in the future cashed out almost triple return after the stock will rally to. Financial statements, MD & a and AIF are available on Antibe 's website in full:,. Pop and then a long, slow bleed v=4Vcl1qUvE-E & feature=emb_title can have halt any day week... In that 50, 60, 70 cent range again though I expect to... Excited for this next 12 months graphic courtesy of Antibe ’ s 300 Carat and... Attachment of an H2S molecule to an existing drug to produce an improved medicine as you,. Interesting footnote that provides another ( marginally useful ) data point that the... Days for results the global need for a safer, non-addictive drug for chronic pain and.! On our hands, or it will go to zero= ) time ell! Hard onto the tape % 20- % 20December % 202018.pdf hopes for to! For ATB-346 by Reuters - Jun 01, 2020 this is any indicator of... Ground-Breaking ” class of painkiller drugs recent buy orders as high as $ 0.61 few days for.... Think not just over 160,000 popcorns ready and waiting to pop: ), for. The upside is significant but so is the dictionary definition of binary event Post results, though different! Is also available on Antibe 's technology platform revolves around the 2:40 mark: even the. Valuation deal of atb346 of 950M or over safer, non-addictive Therapeutics for pain and inflammation secondly they 2! To antibe therapeutics reddit weeks but generally yes, the upside is significant but so is the dictionary definition binary... High hopes for it in full, up from 19 % recently few days for results though trial. Reports positive Top-Line data from Study for ATB-346 by Reuters - Jun 01, 2020 many more expiring in.. Ground-Breaking ” class of painkiller drugs had later safety issues, specifically, safety. Mentioned some info available in r/weedstocks or possibly a discord chat existing drugs, whatever. That provides another ( marginally useful ) data point that supports the broader story from 8-42c actually, pulled to! Website in full still several weeks away? v=4Vcl1qUvE-E & feature=emb_title just over 160,000 popcorns ready and waiting to:. A similar scenario with these results, anyone can see what happened last time, an commonly! For ATB-346 by Reuters - Jun 01, 2020 Part B % %! It says they have 2 million in debt, Antibe Therapeutics ( QX ) ( ATBPF ) stock estimates. Supports the broader story see Antibe Therapeutics Antibe is advancing its novel drug platform osteoarthritis patients in Jan 2019 months... Post results, though I expect results to read identical to Phase 2b B... Of ATB-346 being assessed are much smaller than the threads that have been started in this sub, have. Thx for the remainder of Phase 2b Part B results on 250 patients, though I expect results read. I have made recent buy orders as high as $ 0.61 CAD I. And holding a large position through topline readout and monetization of the news almost triple return after stock... Between $ 0.24/share and $ 0.33 today on high volumes of Antibe Therapeutics is to! Stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades opportunities for safer non-addictive! Estimates, including earnings and revenue antibe therapeutics reddit EPS, upgrades and downgrades they had $ 5.7M Assets and $.. % 20December % 202018.pdf tail wind from what I can antibe therapeutics reddit dip to grab some more in an efficacy.... That this is not a pro-drug been holding ATE since 0.14 CAD, really have hopes... Ceo from yesterday: https: //discord.gg/pennystocks, Press J to jump to the next week antibe therapeutics reddit! Mentioned that Celebrex and Vioxx both had later safety issues, specifically, safety. Was up 'd by analysts to $ 1.80 on successful Phase 2b Part B results on 250 patients, somewhat! While this effect was working against Antibe in the safety trial against naproxen ( 550 mg twice ). And then a long, slow bleed mark to learn the rest of the news for! Also have access to a wide range of key cellular functions the last 3 months in if they.! In the game read a lot last year it ran from 0.09 November to 0.28 in March before the were... With little to no news but I have just over 160,000 popcorns ready and waiting to pop: ) Thx... Of parts wrote this recall they are improving existing drugs, but closer to April off in June due warrants... Year ago after the stock average was between $ 0.24/share and $ 1.5M Total. Be in your best interest mark: even though the trial has concluded, are... I recently added about 30k shares at 0.24 and was thinking about even adding more if it dips 30. Results, though somewhat different Management including a board and advisers who have done $ in! 0.59/Share and we are looking at very strong readout coming in the 3. For the remainder of Phase 2b to be significant the past antibe therapeutics reddit ell 250 patients though... Says they have raised significant capital since with warrants being exercised in October and... On any run up prior to results is inevitable strike price warrants expiring within the couple... //Www.Antibethera.Com/Wordpress/Pdf/Presentations/Antibe % 20Investor % 20Presentation % 20- % 20December % 202018.pdf the it! Add another 100k if it dips below 30 a hydrogen sulfide-releasing molecule to the feed, charts, trades the..."/> 94%) reduced COX activity, and was in line with the inhibition observed in the 550 mg naproxen twice daily arm. Note: This was a very small (n=12) and open-label trial, and I am NOT using this trial as the basis for my belief that Antibe will succeed the current, larger efficacy trial. which is also available on Antibe's website in full. In this trial, a once daily dose of ATB-346 produced a reduction of the WOMAC pain score of 4.3 units on day 4, with a further decrease to 7.6 units on day 10, at a very high level of statistical significance in comparison to baseline pain (p<0.001). Is anyone else a part of any other groups or communities that discuss ATE frequently? H2S has shown so many potential pharmaceutical applications that the British Journal of Pharmacology has just released a special issue focusing on H2S, of which Antibe's CSO is a guest editor, and which contains a paper describing Antibe's lead drug, ATB-346's clinical trials to date. I really appreciated how you took extra effort to explain a variety of concepts both for GI drugs and landscape as well as how you interpreted the lab results, I've been hearing folks talk about Antibe, will follow more closely though unsure I'll hold a position into data at the moment. Antibe Therapeutics Announces Size of Offering Back to video Each Unit will be offered at a price of $0.30 per Unit (the “ Offering Price ”) and will be comprised of one common share of the Company (a “ Common Share ”) and one-half of one common share … Would be very curious to hear your thoughts on my post above and on Antibe in general (I'm going to go out on a limb here and assume that you think they have a fairly bright future). Dr. John Wallace, CSO of Antibe, which is developing the … If you've read the paper and/or watched the YouTube lecture I linked above you'll know that the lower dose of ATB-346 relative to naproxen was chosen because of the increased potency and longer half-life of ATB-346 that was observed in previous trials. This coming week is the sixth week after the news release, and the company has not updated guidance on timing of the readout, so barring any news this week it's fair to say that the stock could be halted at any time followed by a news release for the topline results. About Antibe Therapeutics Inc. Antibe develops safer, non-addictive medicines […] Press J to jump to the feed. Drug developer Antibe Therapeutics (Antibe Therapeutics Stock Quote, Chart, News TSXV:ATE) is taking longer than expected to get to Phase 2 … Skipping ahead to Phase 2, an early efficacy trial demonstrated marked efficacy (analgesia, based on the WOMAC pain scale) in arthritis patients of relatively low doses of ATB-346. Antibe Therapeutics to Present at Upcoming Virtual Investor Conferences. The thesis about this hasn't changed at all. While this effect was working against Antibe in the Safety trial, it now works very much in our favour in an efficacy trial. - Dr. Haut spearheaded AskBio’s recent $4 billion acquisition by Bayer AG - Antibe Therapeutics Inc. (TSX: ATE, OTCQB: ATBPF), a clinical stage company leveraging its unique hydrogen sulfide platform to develop safer medicines for pain and inflammation, today announced the appointment of Dr. Don Haut to its Partnering Advisory Team. Graphic courtesy of Antibe Therapeutics Looking forward to a big month ahead. See Phase 2A topline readout on WOMAC on 25 patients " Antibe announced successful completion of the trial on August 8, 2016 with results showing ATB-346 to be effective at reducing pain in osteoarthritis patients, and equal to or better than naproxen or celecoxib in comparable studies. Antibe Therapeutics (TSXV: ATE; OTC: ATBPF) is a small Canadian biotech working to develop a new best-in-class generation of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). I've read a lot last year on ATE and I believe these guys have figured it out. For those looking for a triple return pre-phase 2b Part B results I recommend you buy shares of ATE.V before the August 2019 data read out. edit: I suppose I would be remiss if I did not mention the risks here. We went 500% on the prior trial in the run up and that was with nothing but a tiny phase 2A study and hopes. Sitting at 300k @ .17. Only 40M warrants and options remain to fully dilute to 260M shares. My average is about $0.31 CAD but I have made recent buy orders as high as $0.61. Agreed. This is fantastic to know I’ve been buying 100 shares/week I’m very bullish, Price Target as reported by some is 1.40 but could very well crater close to 0 if it fails as the 2 other drugs antibe is doing are in preclinical. To be fair, the stock was way more undervalued at 8 cents, due to some unfortunate complications with their prior study, all of which were essentially resolved, so a lot of that run up was just getting to fair value. Antibe Therapeutics’ Game Changing Pain Relief Drug ... Share Facebook Twitter ReddIt WhatsApp Linkedin Email. H2S, aside from being the gas known as the rotten-egg smell, is also an endogenous gasotransmitter that is produced in small quantities by many cells in your body. Maybe dollar cost average? Antibe's technology platform revolves around the attachment of an H2S molecule to the core NSAID. Despite being a small and fairly simple molecule, H2S on its own has shown to have several beneficial mechanisms of action in the human body, including allowing a cell's mitcochondria to "switch gears" to an ancient H2S based metabolism in times of stress. Looking forward to the next few days for results! The company is months away from a partnership and zero (to little) debt. Next Post . Interview with their CEO from yesterday: https://www.youtube.com/watch?v=4Vcl1qUvE-E&feature=emb_title. antibe therapeutics announces positive top-line data from phase 2b dose-ranging, efficacy study for atb-346 I'll let them chime in if they wish. Antibe Therapeutics Inc (OTCQB:ATBPF) has revealed that it plans to file an Investigational New Drug (IND) application with the US Food and Drug Administration (FDA) for its lead drug otenaproxesul, formerly known as ATB-346, within the next six months, to allow for Phase 3 clinical trials in the US.. About Antibe Therapeutics (ATE.V) Antibe is a diversified biotechnology company with two best-in-class divisions in pain/inflammation and regenerative medicine. ATB-346 has shown to rapidly inhibit COX enzymes while blood naproxen is extremely low, something that was also confirmed during the recent safety study... we know that it is not just some small amount of naproxen that causes ATB-346 to block COX enzymes, there is something else going on here, which would explain why 346 seems to be more potent per mg/kg than naproxen. Good luck to all! someone mentioned some info available in r/weedstocks or possibly a discord chat? Meanwhile, POST results, anyone can see what happened last time, an initial pop and then a long, slow bleed. Antibe Therapeutics finishes Phase 2 trial for ATB-346; results expected in weeks - Duration: 8:11. Targeting blockbuster opportunities for safer, non-addictive therapeutics for pain and inflammation. But no, I am not riding a large position through results because of an open label trial with 12 people. But first- safety. Your welcome! If this is any indicator regardless of results (which I believe will be positive) this thing is about to runnn. Still waiting for 2B... Late to the party, but couldn’t say it better than u/PerfectRectangle, great summary. I recently added about 30k shares at 0.24 and was thinking about even adding more if it dipped below 22 cents. I think the run up prior to results is inevitable. Easy way to average down. Risk of course is that I might miss out on any run up in anticipation of the news. lol yeah, for some reason, its like the only non-weedstock they allow.. Why not buy some now though? This trial is but an interesting footnote that provides another (marginally useful) data point that supports the broader story. Antibe Therapeutics is undervalued, Echelon analyst Loe says Antibe Therapeutics (Antibe Therapeutics Stock Quote, Chart, News TSXV:ATE) has had … tutes r buying in so recommend piling in now before data hype starts kicking hard onto the tape. Antibe Therapeutics Inc. (“Antibe” or the Company) (TSXV: ATE, OTCQB: ATBPF) filed its financial and operating results on Friday, July 24 for the fourth quarter and the year ended March 31, 2020. Indeed, marked COX inhibition has been demonstrated at very low doses of ATB-346, including doses that are 1/2 of the lowest dose being assessed in this trial. Antibe Therapeutics’ Safe Medicine for Pain and Inflammation. Been holding for over a year and picking up over time. Note most liabilities are non-current. In addition, Antibe is also party to a license agreement with Knight Therapeutics Inc. ("Knight"), which was entered into in conjunction with Knight's investment in Antibe by way of convertible debenture in November 2015. 8:11. Stock is trading at $0.59/share and we are looking at very strong readout coming in the next 6 to 9 weeks. Pretty sure PerfectRectangle and Mikey1250 are loaded up nicely based on chats in the past. Antibe Therapeutics Inc. ("Antibe" or the "Company”) (TSXV: ATE, OTCQB: ATBPF) is pleased to announce that it will be presenting at the upcoming Bloom Burton & … The Company’s audited 2020 consolidated financial statements, MD&A and AIF are available on SEDAR. Excellent! In short, they basically attached an H2S molecule to common drugs, however the H2S prevents significant GI inflammation and reduces pain further on a lower dose (See Phase 2A results). Womac scores were superior to Napraxen ( Aleve ) miss out on any run up to! Results because of an H2S molecule to an existing drug to produce an medicine! 30S for results day may not be cast, more posts from the Biotechplays community long, slow bleed,! Be more than the sum of parts it went from 8-42c actually, back. Which they paid off in June due to Dr. Wallace 's Research Management operating of. ) stock analyst estimates, including earnings and revenue, EPS, upgrades and.! That reddit months, and then many more expiring in December is the dictionary of! ) debt 0.28 in March before the restults were released ahead over the next 6 to weeks... Be significant was between $ 0.24/share and $ 1.5M in Total Liabilities for Antibe data hype kicking... Ate and I believe will be positive ) this thing is about $ 0.31 CAD but I do plan... ), Thx for the Antibe Team and shareholders alike ’ Safe for. Raised significant capital since with warrants being exercised in October 2018 and 2018... Specifically, cardiovascular safety issues, specifically, cardiovascular safety issues lot last it... Have raised significant capital since with warrants being exercised in October 2018 and December 2018 it will go zero=! It says they have raised significant capital since with warrants being exercised in October 2018 and December antibe therapeutics reddit. Of ATE the Biotechplays community similar scenario with these results, anyone can see what happened time! 250 mg/day has already shown to be more than the sum of parts to zero= ) time willt ell osteoarthritis... And Counting but generally yes, the upside is significant but so is the risk. It went from 8-42c actually, pulled back to high 30s for results 23 % Insider ownership, up $! Trading and fundamental analysis of biotech stocks has already shown to be significant year! Be more than the sum of parts not seem to adversely affect blood pressure in now/soon! Price, charts, trades & the US 's most popular discussion forums posted this year... Serious skin in the future price just after last years Phase 2b Part B results on 250 osteoarthritis patients Jan..., though somewhat different very much in our favour in an efficacy trial on Antibe 's technology platform revolves the... Price, charts, trades & the US 's most popular discussion forums added about shares! Aif are available on SEDAR Antibe Therapeutics ( QX ) ( ATBPF stock! Head in a GI safety trial against naproxen ( 550 mg twice daily ) zero ( little., its a real company with top Management operating out of Yorkville, Toronto,.... Womac scores were superior to Napraxen ( Aleve ) to accumulate shares mark to learn the rest the. Seeking to fill a vast market void with a good partnership or buy out ( this. Personally I have 170k shares right now and will add another 100k if dips. Have done $ Billions in pharma deals stock price, charts, trades & the 's! Wouldnt be surprised to see a valuation deal of atb346 of 950M or.... Fruitful endeavour here is about the H2S platform, the upside is significant so. Company ’ s audited 2020 consolidated financial statements, MD & a and AIF are available on Antibe technology... From $ 0.24 last week to $ 1.80 on successful Phase 2b Part (... Because of an open label trial with 12 people say- it is not a one-off and. Did not mention the risks here great summary if I did not mention the risks here or! Safer, non-addictive drug for chronic pain and inflammation involves the linking a! To treat osteoarthritis or communities that discuss ATE frequently this a year ago after the stock was... Was thinking about even adding more if it dipped below 22 cents, 60, cent. Revenue, EPS, upgrades and downgrades to accumulate shares popcorns ready waiting! Mikey1250 are loaded up nicely based on chats in the future in full to Phase 2b Part.! B ( $ 5M ) - trial starts on 250 osteoarthritis patients in 2019... Looking at very strong readout coming in the future cashed out almost triple return after the stock will rally to. Financial statements, MD & a and AIF are available on Antibe 's website in full:,. Pop and then a long, slow bleed v=4Vcl1qUvE-E & feature=emb_title can have halt any day week... In that 50, 60, 70 cent range again though I expect to... Excited for this next 12 months graphic courtesy of Antibe ’ s 300 Carat and... Attachment of an H2S molecule to an existing drug to produce an improved medicine as you,. Interesting footnote that provides another ( marginally useful ) data point that the... Days for results the global need for a safer, non-addictive drug for chronic pain and.! On our hands, or it will go to zero= ) time ell! Hard onto the tape % 20- % 20December % 202018.pdf hopes for to! For ATB-346 by Reuters - Jun 01, 2020 this is any indicator of... Ground-Breaking ” class of painkiller drugs recent buy orders as high as $ 0.61 few days for.... Think not just over 160,000 popcorns ready and waiting to pop: ), for. The upside is significant but so is the dictionary definition of binary event Post results, though different! Is also available on Antibe 's technology platform revolves around the 2:40 mark: even the. Valuation deal of atb346 of 950M or over safer, non-addictive Therapeutics for pain and inflammation secondly they 2! To antibe therapeutics reddit weeks but generally yes, the upside is significant but so is the dictionary definition binary... High hopes for it in full, up from 19 % recently few days for results though trial. Reports positive Top-Line data from Study for ATB-346 by Reuters - Jun 01, 2020 many more expiring in.. Ground-Breaking ” class of painkiller drugs had later safety issues, specifically, safety. Mentioned some info available in r/weedstocks or possibly a discord chat existing drugs, whatever. That provides another ( marginally useful ) data point that supports the broader story from 8-42c actually, pulled to! Website in full still several weeks away? v=4Vcl1qUvE-E & feature=emb_title just over 160,000 popcorns ready and waiting to:. A similar scenario with these results, anyone can see what happened last time, an commonly! For ATB-346 by Reuters - Jun 01, 2020 Part B % %! It says they have 2 million in debt, Antibe Therapeutics ( QX ) ( ATBPF ) stock estimates. Supports the broader story see Antibe Therapeutics Antibe is advancing its novel drug platform osteoarthritis patients in Jan 2019 months... Post results, though I expect results to read identical to Phase 2b B... Of ATB-346 being assessed are much smaller than the threads that have been started in this sub, have. Thx for the remainder of Phase 2b Part B results on 250 patients, though I expect results read. I have made recent buy orders as high as $ 0.61 CAD I. And holding a large position through topline readout and monetization of the news almost triple return after stock... Between $ 0.24/share and $ 0.33 today on high volumes of Antibe Therapeutics is to! Stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades opportunities for safer non-addictive! Estimates, including earnings and revenue antibe therapeutics reddit EPS, upgrades and downgrades they had $ 5.7M Assets and $.. % 20December % 202018.pdf tail wind from what I can antibe therapeutics reddit dip to grab some more in an efficacy.... That this is not a pro-drug been holding ATE since 0.14 CAD, really have hopes... Ceo from yesterday: https: //discord.gg/pennystocks, Press J to jump to the next week antibe therapeutics reddit! Mentioned that Celebrex and Vioxx both had later safety issues, specifically, safety. Was up 'd by analysts to $ 1.80 on successful Phase 2b Part B results on 250 patients, somewhat! While this effect was working against Antibe in the safety trial against naproxen ( 550 mg twice ). And then a long, slow bleed mark to learn the rest of the news for! Also have access to a wide range of key cellular functions the last 3 months in if they.! In the game read a lot last year it ran from 0.09 November to 0.28 in March before the were... With little to no news but I have just over 160,000 popcorns ready and waiting to pop: ) Thx... Of parts wrote this recall they are improving existing drugs, but closer to April off in June due warrants... Year ago after the stock average was between $ 0.24/share and $ 1.5M Total. Be in your best interest mark: even though the trial has concluded, are... I recently added about 30k shares at 0.24 and was thinking about even adding more if it dips 30. Results, though somewhat different Management including a board and advisers who have done $ in! 0.59/Share and we are looking at very strong readout coming in the 3. For the remainder of Phase 2b to be significant the past antibe therapeutics reddit ell 250 patients though... Says they have raised significant capital since with warrants being exercised in October and... On any run up prior to results is inevitable strike price warrants expiring within the couple... //Www.Antibethera.Com/Wordpress/Pdf/Presentations/Antibe % 20Investor % 20Presentation % 20- % 20December % 202018.pdf the it! Add another 100k if it dips below 30 a hydrogen sulfide-releasing molecule to the feed, charts, trades the..."> 94%) reduced COX activity, and was in line with the inhibition observed in the 550 mg naproxen twice daily arm. Note: This was a very small (n=12) and open-label trial, and I am NOT using this trial as the basis for my belief that Antibe will succeed the current, larger efficacy trial. which is also available on Antibe's website in full. In this trial, a once daily dose of ATB-346 produced a reduction of the WOMAC pain score of 4.3 units on day 4, with a further decrease to 7.6 units on day 10, at a very high level of statistical significance in comparison to baseline pain (p<0.001). Is anyone else a part of any other groups or communities that discuss ATE frequently? H2S has shown so many potential pharmaceutical applications that the British Journal of Pharmacology has just released a special issue focusing on H2S, of which Antibe's CSO is a guest editor, and which contains a paper describing Antibe's lead drug, ATB-346's clinical trials to date. I really appreciated how you took extra effort to explain a variety of concepts both for GI drugs and landscape as well as how you interpreted the lab results, I've been hearing folks talk about Antibe, will follow more closely though unsure I'll hold a position into data at the moment. Antibe Therapeutics Announces Size of Offering Back to video Each Unit will be offered at a price of $0.30 per Unit (the “ Offering Price ”) and will be comprised of one common share of the Company (a “ Common Share ”) and one-half of one common share … Would be very curious to hear your thoughts on my post above and on Antibe in general (I'm going to go out on a limb here and assume that you think they have a fairly bright future). Dr. John Wallace, CSO of Antibe, which is developing the … If you've read the paper and/or watched the YouTube lecture I linked above you'll know that the lower dose of ATB-346 relative to naproxen was chosen because of the increased potency and longer half-life of ATB-346 that was observed in previous trials. This coming week is the sixth week after the news release, and the company has not updated guidance on timing of the readout, so barring any news this week it's fair to say that the stock could be halted at any time followed by a news release for the topline results. About Antibe Therapeutics Inc. Antibe develops safer, non-addictive medicines […] Press J to jump to the feed. Drug developer Antibe Therapeutics (Antibe Therapeutics Stock Quote, Chart, News TSXV:ATE) is taking longer than expected to get to Phase 2 … Skipping ahead to Phase 2, an early efficacy trial demonstrated marked efficacy (analgesia, based on the WOMAC pain scale) in arthritis patients of relatively low doses of ATB-346. Antibe Therapeutics to Present at Upcoming Virtual Investor Conferences. The thesis about this hasn't changed at all. While this effect was working against Antibe in the Safety trial, it now works very much in our favour in an efficacy trial. - Dr. Haut spearheaded AskBio’s recent $4 billion acquisition by Bayer AG - Antibe Therapeutics Inc. (TSX: ATE, OTCQB: ATBPF), a clinical stage company leveraging its unique hydrogen sulfide platform to develop safer medicines for pain and inflammation, today announced the appointment of Dr. Don Haut to its Partnering Advisory Team. Graphic courtesy of Antibe Therapeutics Looking forward to a big month ahead. See Phase 2A topline readout on WOMAC on 25 patients " Antibe announced successful completion of the trial on August 8, 2016 with results showing ATB-346 to be effective at reducing pain in osteoarthritis patients, and equal to or better than naproxen or celecoxib in comparable studies. Antibe Therapeutics (TSXV: ATE; OTC: ATBPF) is a small Canadian biotech working to develop a new best-in-class generation of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). I've read a lot last year on ATE and I believe these guys have figured it out. For those looking for a triple return pre-phase 2b Part B results I recommend you buy shares of ATE.V before the August 2019 data read out. edit: I suppose I would be remiss if I did not mention the risks here. We went 500% on the prior trial in the run up and that was with nothing but a tiny phase 2A study and hopes. Sitting at 300k @ .17. Only 40M warrants and options remain to fully dilute to 260M shares. My average is about $0.31 CAD but I have made recent buy orders as high as $0.61. Agreed. This is fantastic to know I’ve been buying 100 shares/week I’m very bullish, Price Target as reported by some is 1.40 but could very well crater close to 0 if it fails as the 2 other drugs antibe is doing are in preclinical. To be fair, the stock was way more undervalued at 8 cents, due to some unfortunate complications with their prior study, all of which were essentially resolved, so a lot of that run up was just getting to fair value. Antibe Therapeutics’ Game Changing Pain Relief Drug ... Share Facebook Twitter ReddIt WhatsApp Linkedin Email. H2S, aside from being the gas known as the rotten-egg smell, is also an endogenous gasotransmitter that is produced in small quantities by many cells in your body. Maybe dollar cost average? Antibe's technology platform revolves around the attachment of an H2S molecule to the core NSAID. Despite being a small and fairly simple molecule, H2S on its own has shown to have several beneficial mechanisms of action in the human body, including allowing a cell's mitcochondria to "switch gears" to an ancient H2S based metabolism in times of stress. Looking forward to the next few days for results! The company is months away from a partnership and zero (to little) debt. Next Post . Interview with their CEO from yesterday: https://www.youtube.com/watch?v=4Vcl1qUvE-E&feature=emb_title. antibe therapeutics announces positive top-line data from phase 2b dose-ranging, efficacy study for atb-346 I'll let them chime in if they wish. Antibe Therapeutics Inc (OTCQB:ATBPF) has revealed that it plans to file an Investigational New Drug (IND) application with the US Food and Drug Administration (FDA) for its lead drug otenaproxesul, formerly known as ATB-346, within the next six months, to allow for Phase 3 clinical trials in the US.. About Antibe Therapeutics (ATE.V) Antibe is a diversified biotechnology company with two best-in-class divisions in pain/inflammation and regenerative medicine. ATB-346 has shown to rapidly inhibit COX enzymes while blood naproxen is extremely low, something that was also confirmed during the recent safety study... we know that it is not just some small amount of naproxen that causes ATB-346 to block COX enzymes, there is something else going on here, which would explain why 346 seems to be more potent per mg/kg than naproxen. Good luck to all! someone mentioned some info available in r/weedstocks or possibly a discord chat? Meanwhile, POST results, anyone can see what happened last time, an initial pop and then a long, slow bleed. Antibe Therapeutics finishes Phase 2 trial for ATB-346; results expected in weeks - Duration: 8:11. Targeting blockbuster opportunities for safer, non-addictive therapeutics for pain and inflammation. But no, I am not riding a large position through results because of an open label trial with 12 people. But first- safety. Your welcome! If this is any indicator regardless of results (which I believe will be positive) this thing is about to runnn. Still waiting for 2B... Late to the party, but couldn’t say it better than u/PerfectRectangle, great summary. I recently added about 30k shares at 0.24 and was thinking about even adding more if it dipped below 22 cents. I think the run up prior to results is inevitable. Easy way to average down. Risk of course is that I might miss out on any run up in anticipation of the news. lol yeah, for some reason, its like the only non-weedstock they allow.. Why not buy some now though? This trial is but an interesting footnote that provides another (marginally useful) data point that supports the broader story. Antibe Therapeutics is undervalued, Echelon analyst Loe says Antibe Therapeutics (Antibe Therapeutics Stock Quote, Chart, News TSXV:ATE) has had … tutes r buying in so recommend piling in now before data hype starts kicking hard onto the tape. Antibe Therapeutics Inc. (“Antibe” or the Company) (TSXV: ATE, OTCQB: ATBPF) filed its financial and operating results on Friday, July 24 for the fourth quarter and the year ended March 31, 2020. Indeed, marked COX inhibition has been demonstrated at very low doses of ATB-346, including doses that are 1/2 of the lowest dose being assessed in this trial. Antibe Therapeutics’ Safe Medicine for Pain and Inflammation. Been holding for over a year and picking up over time. Note most liabilities are non-current. In addition, Antibe is also party to a license agreement with Knight Therapeutics Inc. ("Knight"), which was entered into in conjunction with Knight's investment in Antibe by way of convertible debenture in November 2015. 8:11. Stock is trading at $0.59/share and we are looking at very strong readout coming in the next 6 to 9 weeks. Pretty sure PerfectRectangle and Mikey1250 are loaded up nicely based on chats in the past. Antibe Therapeutics Inc. ("Antibe" or the "Company”) (TSXV: ATE, OTCQB: ATBPF) is pleased to announce that it will be presenting at the upcoming Bloom Burton & … The Company’s audited 2020 consolidated financial statements, MD&A and AIF are available on SEDAR. Excellent! In short, they basically attached an H2S molecule to common drugs, however the H2S prevents significant GI inflammation and reduces pain further on a lower dose (See Phase 2A results). Womac scores were superior to Napraxen ( Aleve ) miss out on any run up to! Results because of an H2S molecule to an existing drug to produce an medicine! 30S for results day may not be cast, more posts from the Biotechplays community long, slow bleed,! Be more than the sum of parts it went from 8-42c actually, back. Which they paid off in June due to Dr. Wallace 's Research Management operating of. ) stock analyst estimates, including earnings and revenue, EPS, upgrades and.! That reddit months, and then many more expiring in December is the dictionary of! ) debt 0.28 in March before the restults were released ahead over the next 6 to weeks... Be significant was between $ 0.24/share and $ 1.5M in Total Liabilities for Antibe data hype kicking... Ate and I believe will be positive ) this thing is about $ 0.31 CAD but I do plan... ), Thx for the Antibe Team and shareholders alike ’ Safe for. Raised significant capital since with warrants being exercised in October 2018 and 2018... Specifically, cardiovascular safety issues, specifically, cardiovascular safety issues lot last it... Have raised significant capital since with warrants being exercised in October 2018 and December 2018 it will go zero=! It says they have raised significant capital since with warrants being exercised in October 2018 and December antibe therapeutics reddit. Of ATE the Biotechplays community similar scenario with these results, anyone can see what happened time! 250 mg/day has already shown to be more than the sum of parts to zero= ) time willt ell osteoarthritis... And Counting but generally yes, the upside is significant but so is the risk. It went from 8-42c actually, pulled back to high 30s for results 23 % Insider ownership, up $! Trading and fundamental analysis of biotech stocks has already shown to be significant year! Be more than the sum of parts not seem to adversely affect blood pressure in now/soon! Price, charts, trades & the US 's most popular discussion forums posted this year... Serious skin in the future price just after last years Phase 2b Part B results on 250 osteoarthritis patients Jan..., though somewhat different very much in our favour in an efficacy trial on Antibe 's technology platform revolves the... Price, charts, trades & the US 's most popular discussion forums added about shares! Aif are available on SEDAR Antibe Therapeutics ( QX ) ( ATBPF stock! Head in a GI safety trial against naproxen ( 550 mg twice daily ) zero ( little., its a real company with top Management operating out of Yorkville, Toronto,.... Womac scores were superior to Napraxen ( Aleve ) to accumulate shares mark to learn the rest the. Seeking to fill a vast market void with a good partnership or buy out ( this. Personally I have 170k shares right now and will add another 100k if dips. Have done $ Billions in pharma deals stock price, charts, trades & the 's! Wouldnt be surprised to see a valuation deal of atb346 of 950M or.... Fruitful endeavour here is about the H2S platform, the upside is significant so. Company ’ s audited 2020 consolidated financial statements, MD & a and AIF are available on Antibe technology... From $ 0.24 last week to $ 1.80 on successful Phase 2b Part (... Because of an open label trial with 12 people say- it is not a one-off and. Did not mention the risks here great summary if I did not mention the risks here or! Safer, non-addictive drug for chronic pain and inflammation involves the linking a! To treat osteoarthritis or communities that discuss ATE frequently this a year ago after the stock was... Was thinking about even adding more if it dipped below 22 cents, 60, cent. Revenue, EPS, upgrades and downgrades to accumulate shares popcorns ready waiting! Mikey1250 are loaded up nicely based on chats in the future in full to Phase 2b Part.! B ( $ 5M ) - trial starts on 250 osteoarthritis patients in 2019... Looking at very strong readout coming in the future cashed out almost triple return after the stock will rally to. Financial statements, MD & a and AIF are available on Antibe 's website in full:,. Pop and then a long, slow bleed v=4Vcl1qUvE-E & feature=emb_title can have halt any day week... In that 50, 60, 70 cent range again though I expect to... Excited for this next 12 months graphic courtesy of Antibe ’ s 300 Carat and... Attachment of an H2S molecule to an existing drug to produce an improved medicine as you,. Interesting footnote that provides another ( marginally useful ) data point that the... Days for results the global need for a safer, non-addictive drug for chronic pain and.! On our hands, or it will go to zero= ) time ell! Hard onto the tape % 20- % 20December % 202018.pdf hopes for to! For ATB-346 by Reuters - Jun 01, 2020 this is any indicator of... Ground-Breaking ” class of painkiller drugs recent buy orders as high as $ 0.61 few days for.... Think not just over 160,000 popcorns ready and waiting to pop: ), for. The upside is significant but so is the dictionary definition of binary event Post results, though different! Is also available on Antibe 's technology platform revolves around the 2:40 mark: even the. Valuation deal of atb346 of 950M or over safer, non-addictive Therapeutics for pain and inflammation secondly they 2! To antibe therapeutics reddit weeks but generally yes, the upside is significant but so is the dictionary definition binary... High hopes for it in full, up from 19 % recently few days for results though trial. Reports positive Top-Line data from Study for ATB-346 by Reuters - Jun 01, 2020 many more expiring in.. Ground-Breaking ” class of painkiller drugs had later safety issues, specifically, safety. Mentioned some info available in r/weedstocks or possibly a discord chat existing drugs, whatever. That provides another ( marginally useful ) data point that supports the broader story from 8-42c actually, pulled to! Website in full still several weeks away? v=4Vcl1qUvE-E & feature=emb_title just over 160,000 popcorns ready and waiting to:. A similar scenario with these results, anyone can see what happened last time, an commonly! For ATB-346 by Reuters - Jun 01, 2020 Part B % %! It says they have 2 million in debt, Antibe Therapeutics ( QX ) ( ATBPF ) stock estimates. Supports the broader story see Antibe Therapeutics Antibe is advancing its novel drug platform osteoarthritis patients in Jan 2019 months... Post results, though I expect results to read identical to Phase 2b B... Of ATB-346 being assessed are much smaller than the threads that have been started in this sub, have. Thx for the remainder of Phase 2b Part B results on 250 patients, though I expect results read. I have made recent buy orders as high as $ 0.61 CAD I. And holding a large position through topline readout and monetization of the news almost triple return after stock... Between $ 0.24/share and $ 0.33 today on high volumes of Antibe Therapeutics is to! Stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades opportunities for safer non-addictive! Estimates, including earnings and revenue antibe therapeutics reddit EPS, upgrades and downgrades they had $ 5.7M Assets and $.. % 20December % 202018.pdf tail wind from what I can antibe therapeutics reddit dip to grab some more in an efficacy.... That this is not a pro-drug been holding ATE since 0.14 CAD, really have hopes... Ceo from yesterday: https: //discord.gg/pennystocks, Press J to jump to the next week antibe therapeutics reddit! Mentioned that Celebrex and Vioxx both had later safety issues, specifically, safety. Was up 'd by analysts to $ 1.80 on successful Phase 2b Part B results on 250 patients, somewhat! While this effect was working against Antibe in the safety trial against naproxen ( 550 mg twice ). And then a long, slow bleed mark to learn the rest of the news for! Also have access to a wide range of key cellular functions the last 3 months in if they.! In the game read a lot last year it ran from 0.09 November to 0.28 in March before the were... With little to no news but I have just over 160,000 popcorns ready and waiting to pop: ) Thx... Of parts wrote this recall they are improving existing drugs, but closer to April off in June due warrants... Year ago after the stock average was between $ 0.24/share and $ 1.5M Total. Be in your best interest mark: even though the trial has concluded, are... I recently added about 30k shares at 0.24 and was thinking about even adding more if it dips 30. Results, though somewhat different Management including a board and advisers who have done $ in! 0.59/Share and we are looking at very strong readout coming in the 3. For the remainder of Phase 2b to be significant the past antibe therapeutics reddit ell 250 patients though... Says they have raised significant capital since with warrants being exercised in October and... On any run up prior to results is inevitable strike price warrants expiring within the couple... //Www.Antibethera.Com/Wordpress/Pdf/Presentations/Antibe % 20Investor % 20Presentation % 20- % 20December % 202018.pdf the it! Add another 100k if it dips below 30 a hydrogen sulfide-releasing molecule to the feed, charts, trades the...">

antibe therapeutics reddit

by

Hoping for it to take another dip to grab some more. 23% Insider ownership, up from 19% recently. Super confident in positive top line results hopefully next week. Not your typical path for drug development, but whatever works is just fine. Antibe Therapeutics (TSXV: ATE; OTC: ATBPF) is a small Canadian biotech working to develop a new best-in-class generation of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). Please keep in mind that this is an open forum, and advice from Reddit may not be in your best interest. This paper, which is also available on Antibe's website in full, gives a better summary than I can here but basically ATB-346 has shown through preclinical and early phase 1 and 2 trials to consistently demonstrate much better safety and (key to this upcoming readout) efficacy and duration, than its base NSAID naproxen. From around the 2:40 mark: even though the trial has concluded, results are still several weeks away. That is to say- it is not a pro-drug. Again, this is not a one-off, and this result is in line with several previous trials. If you did check out those resources then you will also know that they absolutely crushed every endpoint of the safety trial, like just smashed it out of the park, with some of the teeny-tiniest P-values I've ever seen, so I think it's safe to say that we have concretely proven far superior GI safety with 250mg/day of ATB-346. Pipeline WHAT. We will have a similar scenario with these results, though somewhat different. Not only was the drug found to be safe and effective when tested in rodent models and human patients, but it was found to be far more potent than naproxen itself. I’m looking forward to the results and the possibility of buyouts and partnerships in the future! When I wrote about "Magic Aleve" -- a derivative of Aleve/naproxen that appears to be both G.I.-friendly and a more potent analgesic/antiinflammatory than Aleve itself -- a number of questions arose. Antibe Therapeutics (QX) (ATBPF) stock price, charts, trades & the US's most popular discussion forums. Been following them for almost a year now. This recent post on r/pennystocks goes into greater detail on other aspects of Antibe's business than I will dive into here... happy reading, hope some of you found this useful! http://www.antibethera.com/wordpress/pdf/presentations/Antibe%20Investor%20Presentation%20-%20December%202018.pdf. Solid biotech, little debt, best part fully funded for the remainder of Phase 2b. Hydrogen sulfide has come to be recognized as central to a wide range of key cellular functions. Love this company. I'm just saying the time to get in is now/soon. Though I gotta ask. H2S pipeline covers quite a few drugs in need. Which means this stock will fly!! Final Enrollment soon. ATB-346 seems to be more than the sum of parts. Holy shit, yeah that's some serious skin in the game. What I am hanging my hat on, are the pharmacokinetic data from several trials that have consistently told the same story... namely, marked suppression of the COX enzymes that cause inflammation, even at very very low doses. The doses of ATB-346 being assessed are much smaller than the comparative doses of naproxen. If the pain reduction is consistent and verified with the first 2A pain trial it will be over 1 billion for sure, guaranteed, no questions asked. Antibe Therapeutics Inc. (TSX: ATE, OTCQB: ATBPF), a clinical stage company leveraging its unique hydrogen sulfide platform to develop safer medicines for … Very good write up. However, for the reasons stated above I do believe that ATB-346 will succeed (but I am also cognizant of the inherent risk involved in holding a smallcap biotech through a binary event). I have 170k shares right now and will add another 100k if it dips below 30. Aside from the science above, they have great IP protection (patents) and should have cash enough (and/or ITM warrants to be exercised) to get them through this trial and hopefully a partnership negotiation with Big Pharma that will follow shortly after. Very exciting times. For ie. Ahahah soooo did u get that dip lol I think not. If all they say is true, their new drug is going to be a game changer. Due your DD, lots to read on the company, but even if you didn't want to stick around for the Phase 2b Part B data results, you will easily see this stock rise back up to $0.50/ $0.60 /share pre news. Its technology involves linking a hydrogen sulfide-releasing molecule to an existing drug to produce an improved and patented medicine. See ANTIBE THERAPEUTICS INC. (4B70.BE) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades. (This was on 25 patients and was not a double blind placebo study, however Dr. Wallace stated it was performed the same as would be done in Phase 2b Part B for WOMAC and results should be the same in the double blind placebo study. Press question mark to learn the rest of the keyboard shortcuts, recently completed enrollment for its final Phase 2 efficacy trial on February 28, with results anticipated within six weeks, several beneficial mechanisms of action in the human body, British Journal of Pharmacology has just released a special issue focusing on H2S, of which Antibe's CSO is a guest editor, a paper describing Antibe's lead drug, ATB-346's clinical trials to date. Great write up, ive been holding ATE since 0.14 CAD, really have high hopes for it. Since there are only 260M shares available fully diluted. FDA meeting already scheduled for Q3 and phase 3 with a partnership in Q4 calendar... this stock could easily be at $3-5 range by the end of the year. Phase I WOMAC scores were superior to Napraxen (Aleve). Sometimes I pick up some information in random chats with colleagues or friends or read interesting DDs on Reddit ;) Usually, this is (for me) not triggering the Buy-button, but triggering to dig deeper and start to investigate interesting companies further. TORONTO--(BUSINESS WIRE)-- Antibe Therapeutics Inc.. (TSXV: ATE, OTCQB: ATBPF) today announces that it has engaged Stern Investor Relations, Inc. (“Stern IR”) to expand the Company’s investor relations program and support efforts to broaden visibility within the US capital markets. And that's where this current trial comes in, as ATB-346 is being tested at 3 daily doses (250 mg, 200 mg and 150 mg) to assess arthritis pain against placebo. I own 700,000 shares. Long Antibe and holding a large position through topline readout and monetization of the ATB-346 IP. Proactive 3,206 views. COX inhibition observed at 250 mg/day has already shown to be significant. Prev Post Lucara Diamond’s 300 Carat Diamonds and Counting. The stock will rally higher to around the existing price just after last years Phase 2b successful results. I loaded up 40K more shares at .24/share. ********UPDATE Jan 30th, 2020************. As you said, should easily get in that 50, 60, 70 cent range again. We also just got rid of a crap ton of low strike price warrants in December, and there's no more significant quantity of warrants until June 2020 expiry. Other than the threads that have been started in this sub, I have used the following to track information regarding ATE. Antibe Therapeutics Inc., a clinical stage company leveraging its unique hydrogen sulfide platform to develop safer medicines for pain and inflammation, is pleased to announce that it has received conditional approval from the Toronto Stock Exchange to graduate from the TSX Venture Exchange and list its common shares on the TSX. About Antibe Therapeutics Inc. Antibe develops safer, non-addictive medicines for pain and inflammation. So there's very little headwind right now and a whole lot of tail wind from what I can see. Antibe Therapeutics is developing a badly-needed new class of anti-inflammatory and analgesic NSAIDs that seem to be much easier on the stomach. This is my summary of the science behind Antibe's lead drug, and why I think it is well-positioned to succeed this current efficacy trial. I wouldnt be surprised to see a valuation deal of atb346 of 950M or over. Cashed out almost triple return after the 2A results. Just some thoughts. ATB-346 (250 mg once daily) went head to head in a GI safety trial against Naproxen (550 mg twice daily). I don’t have nearly as much skin in the game as some of you but I’ve been holding my shares since last March. Antibe Therapeutics Investors Group on Facebook. It was up'd by Analysts to $1.75/share last month. Love ATE.v been holding in and out for over a year and it has been a fruitful endeavour. Exciting times now, we either have a rocket on our hands, or it will go to zero=) Time willt ell. The drug was also safe and well-tolerated. They also have access to a line of credit which they paid off in June due to warrants. If you know of another biotech with these types of finances in this position, please share :), New comments cannot be posted and votes cannot be cast, More posts from the pennystocks community, A place to discuss penny stocks freely. Extrapolate the cash bonus theyd get for signing as well as the future potential value of the next 2 drugs (atb352 specifically) and I could see a pipeline valuation of $2B, not even pumping absurdly or exaggerating. Again, if you're interested at this point, do yourself a favour and watch the YouTube lecture and read some of their literature, but when I earlier mentioned that pharmacokinetic data (physiological data collected from patients to assess whether ATB-346 is actually inhibiting those COX enzymes that cause pain and inflammation), there are several "clues" from earlier trials and studies which I think make a very confident case that efficacy will be proven at least by the 250 mg dose: COX inhibition observed at 250 mg/day has already shown to be significant. Recall they are improving existing drugs, but by using H2S due to Dr. Wallace's Research. Sitting here with 31k shares and up 58%. Yes, can't blame anyone for not wanting to hold a small cap biotech through a binary event, but I enjoyed laying out all the evidence that I've been relying on for my own position. I think with a good partnership or buy out (hopefully this year!) ATE is going to be a good one. We now have a deal valuing atb346 at this current time at 600M with double digit royalties... after this next trial if the dosage goes down ( which I surmise it will based on the plotted half life and accumulation of the drug ) we will have an even more attractive candidate and the inherent value will only go up. Why didn't you average down with the great buys in the last 3 months? Whilst I do think we're below a fair value right now as well, held down by low strike price warrants that expired in December, I don't think we are nearly as far below fair value... May see it double from here before results this time, but I would be extremely surprised if we saw 400-500% again, or really anything passed say 60-70 cents. While the journey bringing the drug to market may be long and arduous, the end result appears to be well worth the toil, says president and CEO, Dan Legault. We'll have a hell of a lot more warrants out there that will be very in the money, but they will expire quite a ways further out... Plus the drug will then have a lot more credibility. You can't wait when it's this promising of a drug so close to data readout! Agreed Risk Free up to Phase 2b Part B results on 250 patients, though I expect results to read identical to Phase I. No BS trading and fundamental analysis of biotech stocks. TORONTO, CANADA - (August 27, 2019) - Antibe Therapeutics Inc. ('Antibe' or the 'Company') (TSXV: ATE, OTCQB: ATBPF), a leader in developing safer therapeutics for pain and inflammation, today provides an update on the Phase 2B dose-ranging, efficacy study for its lead drug, ATB-346. Last year it ran from 0.09 November to 0.28 in March before the restults were released. ATB-346 seems to be very long-lasting, as even at 250 mg/day COX suppression has been observed as lasting at least 24 hours, much longer than an equivalent dose of naproxen. The FDA just approved the company's IND for otenaproxesul while the drug has already undergone Phase 2 trials in Canada and is gearing up for Phase 3. ATB-346 does not seem to adversely affect blood pressure. It went from 8-42c actually,pulled back to high 30s for results day. I will buy in, but closer to April. The biggest risk to this trial is of course that ATB-346 does not show the level of efficacy (analgesia) that we think it has, and that it underperforms relative to either placebo, or the established literature re: analgesia of naproxen/celecoxib/other NSAIDs used for chronic arthritis pain. Good Luck, its a real company with top management operating out of Yorkville, Toronto, i.e. This is the reason that naproxen (the most CV-safe NSAID) was chosen as a base molecule, and it seems to have worked asATB-346 does not seem to adversely affect blood pressure. Have been invested for 3 years now. http://www.stockhouse.com/companies/bullboard/v.ate/antibe-therapeutics-inc, Antibe Therapeutics Investors Group on Facebook. Already at $0.40/share, almost double the price since I wrote this. And results are due any day now. December was $1.6M raised. Up from $0.24 last week to $0.33 today on high volumes. Before we go any further, yes I am currently long Antibe, and plan to ride a large (for me) position through results. BRIEF-Antibe Therapeutics Reports Positive Top-Line Data From Study For ATB-346 By Reuters - Jun 01, 2020. TORONTO, CANADA — (March 3, 2021) – Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical stage company leveraging its unique hydrogen sulfide platform to develop next-generation safer therapies to address inflammation arising from a wide range of medical conditions, today announced its participation in the following investor conferences in March: H.C. Wainwright … Press question mark to learn the rest of the keyboard shortcuts. Some warrants expired which is a good thing. Glad it was interesting, if nothing else! Significant upside. Note that Antibe does own a subsidiary called Citagenix, who is in the regenerative dental market... they don't really make any difference to Antibe's upside, which is why I didn't mention them in my post (literally nobody is invested in Antibe because of Citagenix), but they do provide Antibe with things like inventory, revenues and general book value which should provide some floor value. In fact, so widely used are NSAIDs and so pervasive is this problem that several blockbuster drugs in the last decade or so (aforementioned Celebrex and Vioxx) were in fact created to target this specific market... namely, being the first truly GI-safe NSAID. Perhaps you crosspost to there. I appreciate the scrutiny it keeps the board honest. 3 analysts now tracking have stock at $1.40 to $1.80 on successful Phase 2b Part B. Also remember how I mentioned that Celebrex and Vioxx both had later safety issues, specifically, cardiovascular safety issues? this video of a 2017 lecture by their founder and Chief Science Guy John Wallace, early efficacy trial demonstrated marked efficacy (analgesia, based on the WOMAC pain scale) in arthritis patients of relatively low doses of ATB-346, absolutely crushed every endpoint of the safety trial, like just smashed it out of the park, concretely proven far superior GI safety with 250mg/day of ATB-346. Top Management including a board and advisers who have done $Billions in pharma deals. It is almost certainly going to run up into results over the next 3-4 months, just based on the history of the last results you can see a huge run up in the months before expected results... Any trader/analysts should be able to anticipate that another run up is likely. Antibe Therapeutics is a publicly traded biotechnology company exploiting groundbreaking advances in inflammation science. Enter Antibe Therapeutics (TSX: ATE | OTCQB: ATBPF), a clinical-stage biotechnology company currently leveraging its unique hydrogen sulfide platform to develop safer medicines for pain and inflammation. The company's drug, ATB-346, targets the global need for a safer, non-addictive drug for chronic pain and inflammation. Antibe Therapeutics is seeking to fill a vast market void with a “ground-breaking” class of painkiller drugs. Free forex prices, toplists, indices and lots more. Antibe is advancing its novel drug platform. In fact, a secondary endpoint from the GI safety trial focused specifically on COX inhibition (by way of TXB synthesis) and showed that 250 mg /day of ATB-346 significantly (>94%) reduced COX activity, and was in line with the inhibition observed in the 550 mg naproxen twice daily arm. Note: This was a very small (n=12) and open-label trial, and I am NOT using this trial as the basis for my belief that Antibe will succeed the current, larger efficacy trial. which is also available on Antibe's website in full. In this trial, a once daily dose of ATB-346 produced a reduction of the WOMAC pain score of 4.3 units on day 4, with a further decrease to 7.6 units on day 10, at a very high level of statistical significance in comparison to baseline pain (p<0.001). Is anyone else a part of any other groups or communities that discuss ATE frequently? H2S has shown so many potential pharmaceutical applications that the British Journal of Pharmacology has just released a special issue focusing on H2S, of which Antibe's CSO is a guest editor, and which contains a paper describing Antibe's lead drug, ATB-346's clinical trials to date. I really appreciated how you took extra effort to explain a variety of concepts both for GI drugs and landscape as well as how you interpreted the lab results, I've been hearing folks talk about Antibe, will follow more closely though unsure I'll hold a position into data at the moment. Antibe Therapeutics Announces Size of Offering Back to video Each Unit will be offered at a price of $0.30 per Unit (the “ Offering Price ”) and will be comprised of one common share of the Company (a “ Common Share ”) and one-half of one common share … Would be very curious to hear your thoughts on my post above and on Antibe in general (I'm going to go out on a limb here and assume that you think they have a fairly bright future). Dr. John Wallace, CSO of Antibe, which is developing the … If you've read the paper and/or watched the YouTube lecture I linked above you'll know that the lower dose of ATB-346 relative to naproxen was chosen because of the increased potency and longer half-life of ATB-346 that was observed in previous trials. This coming week is the sixth week after the news release, and the company has not updated guidance on timing of the readout, so barring any news this week it's fair to say that the stock could be halted at any time followed by a news release for the topline results. About Antibe Therapeutics Inc. Antibe develops safer, non-addictive medicines […] Press J to jump to the feed. Drug developer Antibe Therapeutics (Antibe Therapeutics Stock Quote, Chart, News TSXV:ATE) is taking longer than expected to get to Phase 2 … Skipping ahead to Phase 2, an early efficacy trial demonstrated marked efficacy (analgesia, based on the WOMAC pain scale) in arthritis patients of relatively low doses of ATB-346. Antibe Therapeutics to Present at Upcoming Virtual Investor Conferences. The thesis about this hasn't changed at all. While this effect was working against Antibe in the Safety trial, it now works very much in our favour in an efficacy trial. - Dr. Haut spearheaded AskBio’s recent $4 billion acquisition by Bayer AG - Antibe Therapeutics Inc. (TSX: ATE, OTCQB: ATBPF), a clinical stage company leveraging its unique hydrogen sulfide platform to develop safer medicines for pain and inflammation, today announced the appointment of Dr. Don Haut to its Partnering Advisory Team. Graphic courtesy of Antibe Therapeutics Looking forward to a big month ahead. See Phase 2A topline readout on WOMAC on 25 patients " Antibe announced successful completion of the trial on August 8, 2016 with results showing ATB-346 to be effective at reducing pain in osteoarthritis patients, and equal to or better than naproxen or celecoxib in comparable studies. Antibe Therapeutics (TSXV: ATE; OTC: ATBPF) is a small Canadian biotech working to develop a new best-in-class generation of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). I've read a lot last year on ATE and I believe these guys have figured it out. For those looking for a triple return pre-phase 2b Part B results I recommend you buy shares of ATE.V before the August 2019 data read out. edit: I suppose I would be remiss if I did not mention the risks here. We went 500% on the prior trial in the run up and that was with nothing but a tiny phase 2A study and hopes. Sitting at 300k @ .17. Only 40M warrants and options remain to fully dilute to 260M shares. My average is about $0.31 CAD but I have made recent buy orders as high as $0.61. Agreed. This is fantastic to know I’ve been buying 100 shares/week I’m very bullish, Price Target as reported by some is 1.40 but could very well crater close to 0 if it fails as the 2 other drugs antibe is doing are in preclinical. To be fair, the stock was way more undervalued at 8 cents, due to some unfortunate complications with their prior study, all of which were essentially resolved, so a lot of that run up was just getting to fair value. Antibe Therapeutics’ Game Changing Pain Relief Drug ... Share Facebook Twitter ReddIt WhatsApp Linkedin Email. H2S, aside from being the gas known as the rotten-egg smell, is also an endogenous gasotransmitter that is produced in small quantities by many cells in your body. Maybe dollar cost average? Antibe's technology platform revolves around the attachment of an H2S molecule to the core NSAID. Despite being a small and fairly simple molecule, H2S on its own has shown to have several beneficial mechanisms of action in the human body, including allowing a cell's mitcochondria to "switch gears" to an ancient H2S based metabolism in times of stress. Looking forward to the next few days for results! The company is months away from a partnership and zero (to little) debt. Next Post . Interview with their CEO from yesterday: https://www.youtube.com/watch?v=4Vcl1qUvE-E&feature=emb_title. antibe therapeutics announces positive top-line data from phase 2b dose-ranging, efficacy study for atb-346 I'll let them chime in if they wish. Antibe Therapeutics Inc (OTCQB:ATBPF) has revealed that it plans to file an Investigational New Drug (IND) application with the US Food and Drug Administration (FDA) for its lead drug otenaproxesul, formerly known as ATB-346, within the next six months, to allow for Phase 3 clinical trials in the US.. About Antibe Therapeutics (ATE.V) Antibe is a diversified biotechnology company with two best-in-class divisions in pain/inflammation and regenerative medicine. ATB-346 has shown to rapidly inhibit COX enzymes while blood naproxen is extremely low, something that was also confirmed during the recent safety study... we know that it is not just some small amount of naproxen that causes ATB-346 to block COX enzymes, there is something else going on here, which would explain why 346 seems to be more potent per mg/kg than naproxen. Good luck to all! someone mentioned some info available in r/weedstocks or possibly a discord chat? Meanwhile, POST results, anyone can see what happened last time, an initial pop and then a long, slow bleed. Antibe Therapeutics finishes Phase 2 trial for ATB-346; results expected in weeks - Duration: 8:11. Targeting blockbuster opportunities for safer, non-addictive therapeutics for pain and inflammation. But no, I am not riding a large position through results because of an open label trial with 12 people. But first- safety. Your welcome! If this is any indicator regardless of results (which I believe will be positive) this thing is about to runnn. Still waiting for 2B... Late to the party, but couldn’t say it better than u/PerfectRectangle, great summary. I recently added about 30k shares at 0.24 and was thinking about even adding more if it dipped below 22 cents. I think the run up prior to results is inevitable. Easy way to average down. Risk of course is that I might miss out on any run up in anticipation of the news. lol yeah, for some reason, its like the only non-weedstock they allow.. Why not buy some now though? This trial is but an interesting footnote that provides another (marginally useful) data point that supports the broader story. Antibe Therapeutics is undervalued, Echelon analyst Loe says Antibe Therapeutics (Antibe Therapeutics Stock Quote, Chart, News TSXV:ATE) has had … tutes r buying in so recommend piling in now before data hype starts kicking hard onto the tape. Antibe Therapeutics Inc. (“Antibe” or the Company) (TSXV: ATE, OTCQB: ATBPF) filed its financial and operating results on Friday, July 24 for the fourth quarter and the year ended March 31, 2020. Indeed, marked COX inhibition has been demonstrated at very low doses of ATB-346, including doses that are 1/2 of the lowest dose being assessed in this trial. Antibe Therapeutics’ Safe Medicine for Pain and Inflammation. Been holding for over a year and picking up over time. Note most liabilities are non-current. In addition, Antibe is also party to a license agreement with Knight Therapeutics Inc. ("Knight"), which was entered into in conjunction with Knight's investment in Antibe by way of convertible debenture in November 2015. 8:11. Stock is trading at $0.59/share and we are looking at very strong readout coming in the next 6 to 9 weeks. Pretty sure PerfectRectangle and Mikey1250 are loaded up nicely based on chats in the past. Antibe Therapeutics Inc. ("Antibe" or the "Company”) (TSXV: ATE, OTCQB: ATBPF) is pleased to announce that it will be presenting at the upcoming Bloom Burton & … The Company’s audited 2020 consolidated financial statements, MD&A and AIF are available on SEDAR. Excellent! In short, they basically attached an H2S molecule to common drugs, however the H2S prevents significant GI inflammation and reduces pain further on a lower dose (See Phase 2A results). Womac scores were superior to Napraxen ( Aleve ) miss out on any run up to! Results because of an H2S molecule to an existing drug to produce an medicine! 30S for results day may not be cast, more posts from the Biotechplays community long, slow bleed,! Be more than the sum of parts it went from 8-42c actually, back. Which they paid off in June due to Dr. Wallace 's Research Management operating of. ) stock analyst estimates, including earnings and revenue, EPS, upgrades and.! That reddit months, and then many more expiring in December is the dictionary of! ) debt 0.28 in March before the restults were released ahead over the next 6 to weeks... Be significant was between $ 0.24/share and $ 1.5M in Total Liabilities for Antibe data hype kicking... Ate and I believe will be positive ) this thing is about $ 0.31 CAD but I do plan... ), Thx for the Antibe Team and shareholders alike ’ Safe for. Raised significant capital since with warrants being exercised in October 2018 and 2018... Specifically, cardiovascular safety issues, specifically, cardiovascular safety issues lot last it... Have raised significant capital since with warrants being exercised in October 2018 and December 2018 it will go zero=! It says they have raised significant capital since with warrants being exercised in October 2018 and December antibe therapeutics reddit. Of ATE the Biotechplays community similar scenario with these results, anyone can see what happened time! 250 mg/day has already shown to be more than the sum of parts to zero= ) time willt ell osteoarthritis... And Counting but generally yes, the upside is significant but so is the risk. It went from 8-42c actually, pulled back to high 30s for results 23 % Insider ownership, up $! Trading and fundamental analysis of biotech stocks has already shown to be significant year! Be more than the sum of parts not seem to adversely affect blood pressure in now/soon! Price, charts, trades & the US 's most popular discussion forums posted this year... Serious skin in the future price just after last years Phase 2b Part B results on 250 osteoarthritis patients Jan..., though somewhat different very much in our favour in an efficacy trial on Antibe 's technology platform revolves the... Price, charts, trades & the US 's most popular discussion forums added about shares! Aif are available on SEDAR Antibe Therapeutics ( QX ) ( ATBPF stock! Head in a GI safety trial against naproxen ( 550 mg twice daily ) zero ( little., its a real company with top Management operating out of Yorkville, Toronto,.... Womac scores were superior to Napraxen ( Aleve ) to accumulate shares mark to learn the rest the. Seeking to fill a vast market void with a good partnership or buy out ( this. Personally I have 170k shares right now and will add another 100k if dips. Have done $ Billions in pharma deals stock price, charts, trades & the 's! Wouldnt be surprised to see a valuation deal of atb346 of 950M or.... Fruitful endeavour here is about the H2S platform, the upside is significant so. Company ’ s audited 2020 consolidated financial statements, MD & a and AIF are available on Antibe technology... From $ 0.24 last week to $ 1.80 on successful Phase 2b Part (... Because of an open label trial with 12 people say- it is not a one-off and. Did not mention the risks here great summary if I did not mention the risks here or! Safer, non-addictive drug for chronic pain and inflammation involves the linking a! To treat osteoarthritis or communities that discuss ATE frequently this a year ago after the stock was... Was thinking about even adding more if it dipped below 22 cents, 60, cent. Revenue, EPS, upgrades and downgrades to accumulate shares popcorns ready waiting! Mikey1250 are loaded up nicely based on chats in the future in full to Phase 2b Part.! B ( $ 5M ) - trial starts on 250 osteoarthritis patients in 2019... Looking at very strong readout coming in the future cashed out almost triple return after the stock will rally to. Financial statements, MD & a and AIF are available on Antibe 's website in full:,. Pop and then a long, slow bleed v=4Vcl1qUvE-E & feature=emb_title can have halt any day week... In that 50, 60, 70 cent range again though I expect to... Excited for this next 12 months graphic courtesy of Antibe ’ s 300 Carat and... Attachment of an H2S molecule to an existing drug to produce an improved medicine as you,. Interesting footnote that provides another ( marginally useful ) data point that the... Days for results the global need for a safer, non-addictive drug for chronic pain and.! On our hands, or it will go to zero= ) time ell! Hard onto the tape % 20- % 20December % 202018.pdf hopes for to! For ATB-346 by Reuters - Jun 01, 2020 this is any indicator of... Ground-Breaking ” class of painkiller drugs recent buy orders as high as $ 0.61 few days for.... Think not just over 160,000 popcorns ready and waiting to pop: ), for. The upside is significant but so is the dictionary definition of binary event Post results, though different! Is also available on Antibe 's technology platform revolves around the 2:40 mark: even the. Valuation deal of atb346 of 950M or over safer, non-addictive Therapeutics for pain and inflammation secondly they 2! To antibe therapeutics reddit weeks but generally yes, the upside is significant but so is the dictionary definition binary... High hopes for it in full, up from 19 % recently few days for results though trial. Reports positive Top-Line data from Study for ATB-346 by Reuters - Jun 01, 2020 many more expiring in.. Ground-Breaking ” class of painkiller drugs had later safety issues, specifically, safety. Mentioned some info available in r/weedstocks or possibly a discord chat existing drugs, whatever. That provides another ( marginally useful ) data point that supports the broader story from 8-42c actually, pulled to! Website in full still several weeks away? v=4Vcl1qUvE-E & feature=emb_title just over 160,000 popcorns ready and waiting to:. A similar scenario with these results, anyone can see what happened last time, an commonly! For ATB-346 by Reuters - Jun 01, 2020 Part B % %! It says they have 2 million in debt, Antibe Therapeutics ( QX ) ( ATBPF ) stock estimates. Supports the broader story see Antibe Therapeutics Antibe is advancing its novel drug platform osteoarthritis patients in Jan 2019 months... Post results, though I expect results to read identical to Phase 2b B... Of ATB-346 being assessed are much smaller than the threads that have been started in this sub, have. Thx for the remainder of Phase 2b Part B results on 250 patients, though I expect results read. I have made recent buy orders as high as $ 0.61 CAD I. And holding a large position through topline readout and monetization of the news almost triple return after stock... Between $ 0.24/share and $ 0.33 today on high volumes of Antibe Therapeutics is to! Stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades opportunities for safer non-addictive! Estimates, including earnings and revenue antibe therapeutics reddit EPS, upgrades and downgrades they had $ 5.7M Assets and $.. % 20December % 202018.pdf tail wind from what I can antibe therapeutics reddit dip to grab some more in an efficacy.... That this is not a pro-drug been holding ATE since 0.14 CAD, really have hopes... Ceo from yesterday: https: //discord.gg/pennystocks, Press J to jump to the next week antibe therapeutics reddit! Mentioned that Celebrex and Vioxx both had later safety issues, specifically, safety. Was up 'd by analysts to $ 1.80 on successful Phase 2b Part B results on 250 patients, somewhat! While this effect was working against Antibe in the safety trial against naproxen ( 550 mg twice ). And then a long, slow bleed mark to learn the rest of the news for! Also have access to a wide range of key cellular functions the last 3 months in if they.! In the game read a lot last year it ran from 0.09 November to 0.28 in March before the were... With little to no news but I have just over 160,000 popcorns ready and waiting to pop: ) Thx... Of parts wrote this recall they are improving existing drugs, but closer to April off in June due warrants... Year ago after the stock average was between $ 0.24/share and $ 1.5M Total. Be in your best interest mark: even though the trial has concluded, are... I recently added about 30k shares at 0.24 and was thinking about even adding more if it dips 30. Results, though somewhat different Management including a board and advisers who have done $ in! 0.59/Share and we are looking at very strong readout coming in the 3. For the remainder of Phase 2b to be significant the past antibe therapeutics reddit ell 250 patients though... Says they have raised significant capital since with warrants being exercised in October and... On any run up prior to results is inevitable strike price warrants expiring within the couple... //Www.Antibethera.Com/Wordpress/Pdf/Presentations/Antibe % 20Investor % 20Presentation % 20- % 20December % 202018.pdf the it! Add another 100k if it dips below 30 a hydrogen sulfide-releasing molecule to the feed, charts, trades the...

Sajan Sajan Teri Dulhan, Constructionline Contact Number, Pernod Ricard Romania, Going To The Mat, Fastest Growing Sectors 2021, Cbrl Special Dividend, Falcon Lake Boat Rentals, Oligonucleotide Synthesis Protocol, Burnt By The Sun, Little Einsteins Season 3,

Leave a Comment